Myeloid-derived Suppressor Cells in Sepsis

NCT ID: NCT03540797

Last Updated: 2018-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

125 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-07-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed for septic patients, to isolate MDSCs and the correlation of prognosis of sepsis. The purpose of this study hopes to explore the phenomenon and possible mechanisms of MDSCs in patients with severe sepsis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intensive care unit (ICU) patients with sepsis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have known origin of infection .
* Systemic inflammatory response syndrome.

Exclusion Criteria

* age less than 18 years
* pregnancy
* known anaphylactoid reaction to colloid fluids
* a life expectancy less than 24 hours,
* inability to provide informed, written consent
* Patients receiving nephrotoxic drugs,
* admitted to the hospital following a surgical procedure,
* sepsis more than 72 hours when screening .
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chung Fu-Tsai

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chung Fu-Tsai

Attending physician

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chung Gung Memorial Hospital

Linkou District, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fu-Tsai Chung, MD

Role: CONTACT

Phone: +886-3281200

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Fu-Tsai Chung, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB103-6424B

Identifier Type: -

Identifier Source: org_study_id